Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction

Molecular Medicine Reports

Volumn 12, Issue 6, 2015, Pages 8010-8020

  Baba, Itsuko ^a   Egi, Yasuhiro ^a   Utsumi, Hiroyuki ^a   Kakimoto, Tetsuhiro ^a   Suzuki, Kazuo ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Macrophage infiltration; Myofibroblast; Renal interstitial fibrosis; Rho associated coiled coil kinase; Unilateral ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; FASUDIL; HYDROXYFASUDIL; HYDROXYPROLINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RHO KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; KIDNEY FIBROSIS; MACROPHAGE; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL LINE; CELL MOTION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY; KIDNEY DISEASES; MALE; METABOLISM; PATHOLOGY; UPREGULATION; URETERAL OBSTRUCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ACTINS; ANIMALS; CELL LINE; CELL MOVEMENT; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; URETERAL OBSTRUCTION;

EID: 84946763088     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4467     Document Type: Article

References (46)

1. Satoh K, Fukumoto Y and Shimokawa H: Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 301: H287-H296, 2011.
2. Hahmann C and Schroeter T: Rho-kinase inhibitors as therapeutics: From pan inhibition to isoform selectivity. Cell Mol Life Sci 67: 171-177, 2010.
3. Olson MF: Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20: 242-248, 2008.
4. Ming D, Yan BP, Liao JK, Lam YY, Yip GW and Yu CM: Rho-kinase inhibition: A novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 15: 622-629, 2010.
5. Budzyn K, Marley PD and Sobey CG: Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27: 97-104, 2006.
6. Shimokawa H and Rashid M: Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28: 296-302, 2007.
7. Kushiyama T, Oda T, Yamamoto K, Higashi K, Watanabe A, Takechi H, Uchida T, Oshima N, Sakurai Y, Miura S and Kumagai H: Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease. Am J Physiol Renal Physiol 304: F1325-F1334, 2013.
8. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, Ono H and Matsuoka H: Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 25: 1053-1063, 2007.
9. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y and Saruta T: Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 64: 2009-2019, 2003.
10. Xie X, Peng J, Chang X, Huang K, Huang J, Wang S, Shen X, Liu P and Huang H: Activation of RhoA/ROCK regulates NF-B signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol 369: 86-97, 2013.
11. Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, Meng FL, Deng YG and Wang RY: Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin 32: 999-1008, 2011.
12. Li Y, Zhu W, Tao J, Xin P, Liu M, Li J and Wei M: Fasudil protect the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: The differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. PLoS One 7: e48115, 2012.
13. Kentrup D, Reuter S, Schnöckel U, Grabner A, Edemir B, Pavenstädt H, Schober O, Schäfers M, Schlatter E and Büssemaker E: Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in rat renal acute ischemia-reperfusion injury. PLoS One 6: e26419, 2011.
14. Matoba K, Kawanami D, Okada R, Tsukamoto M, Kinoshita J, Ito T, Ishizawa S, Kanazawa Y, Yokota T, Murai N, et al: Rho-kinase inhibition privents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1. Kidney Int 84: 545-554, 2013.
15. Diah S, Zhang GX, Nagai Y, Zhang W, Gang L, Kimura S, Hamid MR, Tamiya T, Nishiyama A and Hitomi H: Aldosterone induced mypfibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 314: 3654-3662, 2008.
16. Wei J, Li Z, Ma C, Zhan F, Wu W, Han H, Huang Y, Li W, Chen D and Peng Y: Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. Cell Biol Int 37: 725-730, 2013.
17. Manickam N, Patel M, Griendling KK, Gorin Y and Barnes JL: RhoA/Rho kinase mediates TGF-1-induced kidney myofibroblast activation through Poldip2/Nox4-derived reactive oxygen species. Am J Physiol Renal Physiol 307: F159-F171, 2014.
18. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E and Hori M: Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61: 1684-1695, 2002.
19. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T and Shimokawa H: Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 455: 169-174, 2002.
20. Takeda Y, Nishikimi T, Akimono K, Matsuoka H and Ishimitsu T: Benefical effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res 33: 965-973, 2010.
21. Kakimoto T, Kimata H, Iwasaki S, Fukunari A and Utsumi H: Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4. J Endocrinol 216: 13-20, 2013.
22. Woessner JF Jr: The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93: 440-447, 1961.
23. Kivirikko KI, Laitinen O and Prockop DJ: Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 19: 249-255, 1967.
24. Chevalier RL, Forbes MS and Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145-1152, 2009.
25. Chevalier RL: Obstructive nephropathy: Towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2: 157-168, 2006.
26. Shen B, Liu X, Fan Y and Qiu J: Macrophages regulate renal fibrosis through modulating TGF superfamily signaling. Inflammation 37: 2076-2084, 2014.
27. Yang HC, Zuo Y and Fogo AB: Models of chronic kidney disease. Drug Discov Today Dis Models 7: 13-19, 2010.
28. Löpez-Novoa JM, Martinez-Salgado C, Rodriguez-Peña AB and López-Hernández FJ: Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives. Pharmacol Ther 128: 61-81, 2010.
29. Truong LD, Gaber L and Eknoyan G: Obstructive uropathy. Contrib Nephrol 169: 311-326, 2011.
30. Eddy AA, López-Guisa JM, Okamura DM and Yamaguchi I: Investigating mechanizes of chronic kidney disease in mouse models. Pediatr Nephrol 27: 1233-1247, 2012.
31. Fu P, Liu F, Su S, Wang W, Huang XR, Entman ML, Schwartz RJ, Wei L and Lan HY: Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 17: 3105-3114, 2006.
32. Ballhause TM, Soldati R and Mertens PR: Sources of myofibroblats in kidney fibrosis: All answers are correct, however to different extent! Int Urol Nephrol 46: 659-664, 2014.
33. Duffield JS: Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124: 2299-2306, 2014.
34. Pan SY, Chang YT and Lin SL: Microvascular pericytes in healthy and diseased kidneys. Int J Nephrol Renovascul Disease 7: 39-48, 2014.
35. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Wada C, Sugimoto H and Kalluri R: Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19: 1047-1053, 2013.
36. Jang HS, Kim JI, Jung KJ, Kim J, Han KH and Park KM: Bone marrow-derived cells play a major role in kidney fibrosis via proliferation and differentiation in the infiltrated site. Biochim Biophys Acta 1832: 817-825, 2013.
37. Qin J, Xie YY, Huang L, Yuan QJ, Mei WJ, Yuan XN, Hu GY, Cheng GJ, Tao LJ and Peng ZZ: Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology (Carlton) 18: 690-699, 2013.
38. Gu L, Gao Q, Ni L, Wang M and Shen F: Fasudil inhibits epithelial-myofibroblast transdifferentiation of human renal tubular epithelial HK-2 cells induced by high glucose. Chem Pharm Bull (Tokyo) 61: 688-694, 2013.
39. Gande MT, Pèrez-Barriocanal F and López-Novoa JM: Role of inflammation in tubule-interstitial damage associated to obstructive nephropathy. J Inflamm (Lond) 7: 19, 2010.
40. Wang Y and Harris DC: Macrophages in renal disease. J Am Soc Nephrol 22: 21-27, 2011.
41. Chung AC and Lan HY: Chemokines in renal injury. J Am Soc Nephrol 22: 802-809, 2011.
42. Liu N, Tolbert E, Pang M, Ponnusamy MI, Yan H and Zhuang S,: Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22: 1064-1075, 2011.
43. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, Chin YE, Yan H, Dworkin LD and Zhuang S: A novel STAT3 inhibitor, S31-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78: 257-268, 2010.
44. Meng XM, Huang XR, Xiao J, Chen HY, Zhong X, Chung AC and Lan HY: Diverse roles of TGF-receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol 227: 175-188, 2012.
45. Anders HJ and Ryu M: Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925, 2011.
46. Ricardo SD, van Goor H and Eddy AA: Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522-3530, 2008.